AstraZeneca has signed an agreement to divest and license the commercial rights for Seroquel and Seroquel XR in Europe and Russia to German pharmaceutical company Cheplapharm Arzneimittel.
30 October 2019 News
23 October 2019 News
Biogen and its partner Eisai have announced plans to seek the US Food and Drug Administration (FDA) approval for an investigational drug, aducanumab, to treat early Alzheimer’s disease (AD).
20 September 2019 Research Reports
Spinal muscular atrophy (SMA) is a group of neurological disorders that cause a loss in muscle movement due to depleting motor neurons and progressive muscle wasting. The disease can be...
20 September 2019 Analysis
One approach to overcome continuing challenges facing drug research and development for Alzheimer’s is a vaccine. Swiss AC Immune has developed an Abeta-focused vaccine called ACI-24, which has been both...
19 September 2019 News
Novartis subsidiary AveXis has announced interim data for Zolgensma (onasemnogene abeparvovec-xioi) in children with spinal muscular atrophy (SMA) type 1, the most severe form of the neurodegenerative condition, for trials...
16 September 2019 News
Biogen and Eisai have discontinued the clinical development programme of beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat in early Alzheimer’s disease.
13 September 2019 News
Roche has announced Ocrevus (ocrelizumab) reduced the long-term risk of disability progression in patients with relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) in two studies.
3 September 2019 News
Novartis unit Sandoz has signed an agreement with biopharmaceutical firm Polpharma Biologics for exclusive rights to commercialise a proposed biosimilar of Biogen’s multiple sclerosis drug natalizumab.
29 August 2019 News
The US Food and Drug Administration (FDA) has approved Japanese company Kyowa Kirin’s drug Nourianz (istradefylline) as an add-on to the existing drug levodopa/carbidopa to treat adults with Parkinson’s disease...